Friday, November 1, 2013

Go Read Derek Lowe: Merck's New R&D Structure, Critically Considered


Derek is a very smart guy. And he's a former Merck legacy Schering Plough scientist (early 2000s -- UPDATED 11.07.13: thanks to my anonymous commenters -- for correcting this! Excellent!). So I'd pay attention, here.

I'll not tease too much of his thesis -- but it is well-thought out. [And, one comment to his post led me to revampt the masthead last night, post Banksy's one month "residencey" -- in NYC.]

Do go read it all, comments included. Here's a bit:
. . . .So the picture that's emerging of Merck's drug discovery business after this round of cuts is confused, but some general trends seem to be present.

West Point appears to have been very severely affected, with a large number of chemists shown the door, and reports tend to agree that bench chemists were disproportionately hit.

The remaining department would seem to be top-heavy with managers. . . .


He's made quite a few other interesting points. Do go look. And be excellent to one another, today, on All Souls' Day. Celebrate all souls -- all of them!

1 comment:

  1. Dr. Lowe was a former employee of Schering Plough, but left long before the merger with Merck. He is not nor has ever been such an employee. His comments are relevant none-the-less, and he knows many of the individuals affected by Merck's most recent layoff.

    ReplyDelete